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Abstract
Introduction: The aim of this study was determination of troponin I at serum using Architect (Abbott) and 
AxSYM System (Abbott). Troponin is regulatory subunit of the troponin complex associate with actin filament 
within muscle cells and it is a marker for diagnosis of myocardial damage. 
Methods: We used Architect STAT chemiluminescent microparticle immunoassay (CMIA) and AxSYM mic-
roparticle Enzyme Immunoassay (MEIA), techniques for quantitative determination of cardiac TnI in human 
serum or plasma. At our study we have proved precision, reproducibility and accuracy from both methods. 
The investigation included patients (n=119) who have myocardial infarction or ischemic heart damage and 
were treated at cardiology, emergency, internal medicine and neurology unit in Clinical Center University in 
Sarajevo. 
Results: The precision for three controls using Architect STAT TnI asssay technology were 3.6 – 5.2 % and 
reproducibility was 3.7 to 5.6 %. The AxSYM STAT TnI has precision for three controls 4.3–6.6 % and repro-
ducibility was from 4.8 to 7.8 %. We have got very good correlation between Architect and AxSYM technology 
r = 0.999 in the investigation of troponin I in serum.
Conclusions: We can conclude that chemiluminescent troponin assay I (Architect) showed good analytical 
performance and gave new possibility at troponin I determination. © 2011 All rights reserved
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Introduction
Acute myocardial infarction is a major cause of 
death and disability. Approximately 15 million 
patients per year in the United States and Europe 
present to the emergency department with chest 
pain or other symptoms suggestive of acute myo-
cardial infarction (1). Clinical studies have dem-
onstrated the release of troponin concentration 
(cTnI) into the blood steam within hours follow-
ing myocardial infarction (MI) or ischemic dam-
age. Elevated levels of cTnI (above the values es-
tablished for non-MI specimens) are detectable 
in serum within 4 to 6 hours after the onset of 
chest pain, reach peak concentration in approxi-
mately after 8 to 28 hours, and remain elevated 
for 3 to 10 days following MI. Cardiac troponin 
is the preferred biomarker for the detection of 
myocardial injury based on improved sensitivity 
and superior tissue-specificity compared to other 
available biomarkers of necrosis, including CK-
MB, myoglobin, lactate dehydrogenase, and oth-
ers. The high specificity of cTnI measurements is 
beneficial in identify cardiac injury for clinical 
conditions involving skeletal muscle injury result-
ing from surgery, trauma or muscular disease (2). 
The Joint European Society of Cardiology/Ameri-
can College of Cardiology/American Heart As-
sociation/ World Heart Federation Task Force 
redefinition of acute myocardial infarction (AMI) 
is predicated on the detection of increase or de-
crease of cardiac troponin (cTn), with at least 1 
concentration above the 99th presence reference 
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value in patients with evidence of myocardial 
ischemia. Blood samples for measurement of cTn 
are recommended to be drawn at presentation 
and 6-9 h later to optimize clinical sensitivity for 
ruling in AMI (3,4). The Architect STAT chemi-
luminescent microparticle immunoassay (CMIA) 
and AxSYM microparticle Enzyme Immunoas-
say (MEIA), are techniques for quantitative de-
termination of cardiac TnI in human serum or 
plasma. Immunoassays utilize one or more select 
antibodies to detect analytes of interest. Analytes 
being measured may be those that are naturally 
presented in the body, those that the body pro-
duced but are not typically present (such as tro-
ponin antigen). At the CMIA a chemiluminescent 
label conjugated to the antibody or antigen, and it 
produces light when combined with its substrate. 
This method is very similar to MEIA, though the 
chemiluminescent reaction offers high sensitivity 
and ease measurement. A noncompetive sand-
wich format yields results that are directly pro-
portional to the amount of analyte present (5,6). 
Using patient samples collected in our laboratory 
we analyzed troponin concentration by CMIA and 
MEIA technology methods and compared the results. 
Methods
Patients
The patient samples of blood were collected in 
serum separation Vacutainer test tubes (Beckton 
Dickinson, Rutherford, NJ 07,070 U.S.) in vol-
ume of 3.5 mL. We used test tubes with gel. Se-
rum samples were obtained by centrifugation at 
3000 rpm using centrifuge (Sigma 4-10). After 
centrifuging, serum concentration of TnI was 
determined. The investigation was done respect-
ing ethical standards in the Helsinki Declara-
tion. The investigation included patients (n=119) 
in period from February till May in 2008. The 
patients who have myocardial infarction or 
ischemic heart damage were treated at cardiol-
ogy, emergency, internal medicine and neurol-
ogy unit in Clinical Centre University in Sarajevo. 
Chemiluminescent microparticle immunoassay – 
CMIA
All immunoassays require the use of labeled ma-
terial in order to measure the amount of anti-
gen or antibody. A label is a molecule that will 
react as a part of the assay, so a change in signal 
can be measured in the blood after added re-
agent solution. CMIA is noncompetitive sand-
wich assay technology to measure analytes. The 
amount of signal is directly proportional to 
the amount of analyte present in the sample.
Architect STAT Troponin I assay is two-step immu-
noassay to determine the presence TnI in human 
serum using CMIA technology. In the first step, 
sample, assay diluent and anti-troponin-I-anti-
body-coated paramagnetic particles are combined. 
TnI present in the sample binds to the anti-tropo-
nin-I coated microparticles. After incubation and 
wash, anti-troponin-I-acridinium-labeled conju-
gate is added in the second step. Following another 
incubation and wash, pre-trigger and trigger solu-
tions are then added to the reaction mixture. The 
pre-trigger solution (hydrogen peroxide) performs 
the following functions: 1) Creates an acidic envi-
ronment to prevent early release of energy (light 
emission), 2) Helps to keep microparticles from 
clumping, 3) Splits acridinium dye off the conju-
gate bound to the microparticle complex. This ac-
tion prepares the acridinium dye for the next step.
The trigger solution (sodium hydroxide) dis-
penses to the reaction mixture. The acridinium 
undergoes an oxidative reaction when exposed 
to peroxide and an alkaline solution. This reac-
tion causes the chemiluminescent reaction to oc-
cur. N-methylacridone forms and releases energy 
(light emission) as it returns to its ground state.
The resulting chemiluminescent reaction is mea-
sured as relative light units (RLU). A direct relation-
ship exists between the amount of TnI in the sample 
and RLU detected by Architect System optics (2,5). 
Microparticle enzyme immunoassay - MEIA 
MEIA is an immunoassay method that uti-
lizes the isolation of antibody/antigen com-
plexes on solid phase surface of small beads 
called microparticles. It is automate technol-
ogy for measurement of large molecules such 
as markers associate with cardiac testing. 
The proces of the MEIA technology includes: Mic-
roparticles coated with anti-analyte antibodies and 
sample are incubated together to form reaction 
mixture. 1) An aliquot of the reaction mixture is 
transfer to the glass fiber matrix. 2) Alkaline phos-
phatase-labeled anti-analyte antibodies are allowed 
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to bind to the microparticle com-
plex. 3) The substrate 4-methy-
lumbelliferyl phosphate (MUP) 
is added to the matrix. The fluo-
rescent product, methylumbel-
liferone (MU) is measured. The 
flourescent product is measured 
by MEIA optical assemby (4,5).
The AxSym dynamic range is 0.02-
22.8 μg/L and imprecision (10% 
CV): 0.16-0.56 μg/L. The Archi-
tect cTnI dynamic range is 0.01-
50 μg/L and imprecision (10% 
CV): 0.032-0.055 μg/L (7). The patients specimens 
for AxSym greater than 22.78 ng/mL or Architect 
greater than 50 ng/mL we used dilution protocol. 
The CMIA is new immunochemistry technique 
with analytical sensitivity ≤ 0.01 for cTnI detection 
in serum compared with MEIA with analytical sen-
sitivity ≤ 0.02. The advantages of CIMA is detection 
of lowest concentration of troponin that can be 
measured at patents serum after MI (2,3). The ref-
erence range for TnI in serum is 0.00-0.40 ng/mL.
Quality control
The low, medium and high TnI controls of com-
mercially available Architect ABBOTT and 
AxSYM ABBOTT were used. The precision 
(intra-day variation) was tested by measuring 
(n=20) of three different controls of TnI. The 
reproducibility (inter-day variation) for same 
controls was tested all controls once a day over 
10 consecutive days. The accuracy of measur-
ing was tested in 119 of serum patient who were 
determined TnI. Measures were obtained by Ar-
chitect CMIA and AxSYM MEIA technology. 
Statistical analysis 
The results were statistically analyzed using NCSS 
and statistical software SPSS version 12.0 software. 
Determined by the average value (χ), standard 
deviation (SD), Pearson correlation coefficient 
(r), equations of linear regression and Student t 
test with statistical significance level of p <0.05.
Results 
Quality control testing
Three controls low, medium and high Abbott tech-
nology (n = 20) were measured for quality control 
testing. Measurements were done during 10 days 
period. The average value (χ), standard deviation 
(SD) and coefficient of variation (CV) are shown 
in Table 1. The precision has coefficient of varia-
tion (CV) for three controls using Architect STAT 
TnI assay technology were 3.6 – 5.2 %. Reproduc-
ibility was determined by running controls in the 
morning over 10 consecutive day. Coefficient of 
variation (CV) for the reproducibility of TnI assay 
varied from 3.7 to 5.6 %. The precision has coef-
ficient of variation (CV) for three controls using 
AxSYM STAT TnI assay technology were 4.3–6.6 
%. Reproducibility was determined by running 
controls in the morning over 10 consecutive 
day. Coefficient of variation (CV) for the repro-
ducibility of TnI assay varied from 4.8 to 7.8 %. 
Accurancy testing
We compared TnI concentration measured in 
119 blood serum by Architect CMIA and AxSYM 
MEIA technology. The results of the compari-
son between Architect CMIA and AxSYM MEIA 
technology analysis are shown in Figure 1. Siz-
able correlation was noted between Architect and 
AxSYM technology in the investigation of 119 
blood samplers (r = 0.999). Regression equation 
revealed a slope of 0.9187 and a y axis intercept 
of 0.077. The difference between the methods 
was statistically significant for p <0.05 accord-
ing Student t-test. The Architect STAT TnI assay 
had a limit of detection of 0.004 µg/L and a CV 
of 10% at concentrations approaching 0.03 µg/L. 
The concentration of serum TnI using Architect 
CMIA is higher than AxSYM MEIA technology. 
Ten of the 119 samples (in 5 patients) were likely 
















Architect Troponin I assay CmIA technology
0.145  0.155 ± 0.01 5.3 0.144 ± 0.03 5.6
0.580 0.632 ± 0.03 3.9 0.577 ± 0.09 4.9
15.67 16.03 ± 0.82 3.6 15.93 ± 2.49 3.7
AxSym Troponin I assay mEIA technology
0.28 0.30± 0.017 4.3 0.26± 0.026 4.8
1.14 1.15 ± 0.054 4.7 1.11± 0.047 5.2
9.49 9.44 ± 0.627 6.6 9.38± 0.728 7.8
Table 1.  Quality control testing 
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detected cardiac events during follow-up. The Ar-
chitect values in these 10 samples ranged from 0.04 
to 0.09 µg/L. These findings highlight the potential 
of the Architect assay to reclassify patients previ-
ously labeled as "normal". The mean concentration 
of TnI by patients with no detected cardiac events 
in Architect assay was 0.005 µg/L and in AXSYM 
assay was 0.000 g/L. The average concentration of 
TnI in serum from all patients in study measured 
by Architect assay was 16.07 µg/L and in AXSYM 
assay was 14.84 µg/L. The results of the mean 
concentration of Architect CMIA and AxSYM 
MEIA technology analysis are shown in Figure 2. 
Discussion
The Quality control testing using all three controls 
in Architect CMIA and AxSYM MEIA technology 
using Levey – Jennings report were under range of 
two S.D. The CMIA have broader range of controls 
then MEIA technology. The new CMIA technology 
has higher precision and reproducibility of TnI as-
say and better improvement in quality of assay. Our 
results have shown the possibility of detection low-
er concentration of troponin in serum with CIMA. 
The similar results have got other groups (8-10).
The accuracy testing, we found very good correla-
tion between two technologies CMIA and MEIA 
with correlation coefficient r = 0.99. The investi-
gation from Lam at all have found good factor of 
correlation too (8). The methods have correlation 
but great difference in mean troponin concen-
tration patient with MI and low concentration 
of patients that have not myocardial infarction.
We can explain it in difference of troponin mean 
concentration with higher analytical sensitiv-
ity ≤ 0.01 of Architect CMIA in comparison with 
AxSYM MEIA technology with lower analytical 
sensitivity ≤ 0.02. Comparison with the clini-
cally evaluated AxSYM cTnI assay (9-11) showed 
that the Architect STAT TnI assay identified ad-
ditional patients who have not clinical evidence 
of cardiac damage. This is in keeping with studies 
showing that the AxSYM assay may miss patients 
who later developed poor cardiac outcomes. Fur-
thermore, the Architect TnI showed good agree-
ment with the measurement at the lower end of 
range (9,11). At our study we have got possibil-
ity of early detection of troponin in patient se-
rum with CMIA in the moment when the same 
serum was not detectable using MEIA. The mea-
surement of CMIA 0.01-50 μg/L and MEIA 0.02-
22.8 and it can explain better sensibility of CMIA 
technology for detection troponin in serum. 
The definition of high-sensitive assay would be 
one that had total imprecision less than 10 % at 
the 99th percentile. Our 99th percentile value is 
higher than that reported by the manufactur-
er (0.012 µg/L) and may be attributable to our 
use of freshly collected blood bank specimens.
Conclusion
Architect CMIA Abbott technology is an applica-
tive method in monitoring TnI in patients after 
myocardial infarction. In comparing methods we 
have got better precision and reproducibility of 
TnI assay for Architect STAT TnI assay technology 
then AxSYM MEIA technology. CMIA method 
is technology improved and has possibilities for 
detection lower and higher concentration of TnI 
than MEIA. The mean differences between CIMA 
FIGURe 1.  Comparison of TnI concentration (ng/ml) in se-
rum measured by Architect CmIA (x-axis)and AxSym   mEIA 
technology (y-axis).
FIGURe 2.  the comparison of troponin i in patient serum 
using different methods.
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and MEIA methods was statistically significant 
for p <0.05 using Student t test with very good 
factor of correlation r = 0.99. We conclude that 
Architect CMIA Abbott technology is method 
proves reliable TnI concentration in patient se-
rum and it has better precision limits and abil-
ity to detect troponin at the low end of the range.
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